Preventing low platelets from T-DM1 in HER2+ breast cancer
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a drug called herombopag can help prevent low platelet counts, a common side effect of the chemotherapy T-DM1. If you have HER2-positive breast cancer and are about to start T-DM1 treatment, this study may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with HER2-positive breast cancer (a type that has too much of a protein called HER2).
- Your doctor plans to treat you with T-DM1, a targeted chemotherapy drug.
- You are in generally good health aside from cancer (ECOG score 0-2, meaning you can do daily activities).
- You do not have other conditions that cause low platelets (like aplastic anemia or immune thrombocytopenia).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
This trial tests if herombopag can help raise platelet counts in breast cancer patients who have low platelets caused by the drug T-DM1 after prior anti-HER2 therapy. If it works, it may allow you to continue T-DM1 without delays or dose reductions.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.